Gamida Cell Ltd. (GMDA) NASDAQ
$0.03 - (-)
Market Cap: -
As of 04/05/24 12:00 AM EDT. Market closed.
Gamida Cell Ltd. (GMDA)
NASDAQ
$0.03
- (-)
Market Cap: -
As of 04/05/24 12:00 AM EDT. Market closed.
gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the ... read more
gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda. read less
Open in: 
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| WILLS STEPHEN T | Director | Sep 30, 2022 | Buy | $1.55 | 9,677 | 14,999 | 11,677 | Oct 04, 2022, 04:43 PM |
| Tomasello Shawn | Director | Sep 30, 2022 | Buy | $1.55 | 9,677 | 14,999 | 11,677 | Oct 04, 2022, 04:39 PM |
| Jenkins Abigail L. | President and CEO | Sep 30, 2022 | Buy | $1.55 | 16,129 | 25,000 | 266,129 | Oct 04, 2022, 04:19 PM |
| Owner | Relationship | Date | Value($) |
| WILLS STEPHEN T | Director | 09/30/2022 | 14,999 |
| Tomasello Shawn | Director | 09/30/2022 | 14,999 |
| Jenkins Abigail L. | President and CEO | 09/30/2022 | 25,000 |
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ARK INVESTMENT MANAGEMENT LLC | 1,484 | 0% | -99.93% | Growth |
| RENAISSANCE TECHNOLOGIES LLC | 957,581 | 0.00061% | New | Other |
| BLACKROCK INC. | 289,262 | 0% | 30.96% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 83,843 | 0% | 56.87% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View